Concepedia

Infliximab for hidradenitis suppurativa

Thomas P. Sullivan, Esperanza Welsh, Francisco A. Kerdel, Anne E. Burdick, Robert S. Kirsner

British Journal of Dermatology · 2003 · 161 citations · 11 references

DOI

Abstract

Infliximab is a promising agent for the treatment of HS. These initial results suggest that infliximab is associated with objective and subjective improvement in HS. Further controlled studies of the efficacy of infliximab and its effect on the course of the disease are warranted.

References

11

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Joseph Keane, Sharon K. Gershon, Robert P. Wise et al. · New England Journal of Medicine · 2001 · 3.7K citations · Full text

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

Michael J. Elliott, Ravinder N. Maini, Marc Feldmann et al. · The Lancet · 1994 · 1.7K citations

, , +11

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Umesh Chaudhari, Pat Romano, LD Mulcahy et al. · The Lancet · 2001 · 903 citations

, , +10

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

P. Charles, Ruud J.T. Smeenk, Jan de Jong et al. · Arthritis & Rheumatism · 2000 · 530 citations

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

New England Journal of Medicine · 2001 · 333 citations

, ,